Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury

Neurocritical Care

Volumn 14, Issue 3, 2011, Pages 354-360

  Galton, Christopher ^a   Deem, Steven ^b   Yanez, N David ^b   Souter, Michael ^b,c   Chesnut, Randall ^c   Dagal, Armagan ^b   Treggiari, Miriam ^b,c,d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Arginine vasopressin; Clinical trial; Conivaptan; Human; Hyponatremia; Intracranial pressure; Sodium; Vasopressin receptor antagonists

Indexed keywords

CONIVAPTAN; SODIUM;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRACRANIAL PRESSURE; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BALANCE; SODIUM BLOOD LEVEL; SODIUM LOAD; TRAUMATIC BRAIN INJURY; TREATMENT RESPONSE; URINE VOLUME;

ADULT; AGED; BENZAZEPINES; BRAIN INJURIES; DIURESIS; FEMALE; HUMANS; INTRACRANIAL PRESSURE; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN; SODIUM; TREATMENT OUTCOME;

EID: 79955789885     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-011-9525-8     Document Type: Article

References (17)

1. L Rangel-Castilla S Gopinath CS Robertson 2008 Management of intracranial hypertension Neurol Clin 26 521 541 18514825 10.1016/j.ncl.2008.02.003 (Pubitemid 351734581)
2. WL Wright WH Asbury JL Gilmore OB Samuels 2009 Conivaptan for hyponatremia in the neurocritical care unit Neurocrit Care 11 6 13 19003543 10.1007/s12028-008-9152-1 1:CAS:528:DC%2BD1MXotFyms7Y%3D
3. R Dhar T Murphy-Human 2011 A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury Neurocrit Care 14 1 97 102 20440600 10.1007/s12028-010-9366-x
4. T Murphy R Dhar M Diringer 2009 Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit Neurocrit Care 11 14 19 19123060 10.1007/s12028-008-9179-3 1:CAS:528:DC%2BD1MXotFyms7k%3D
5. AM Naidech J Paparello SM Leibling, et al. 2010 Use of conivaptan (Vaprisol) for hyponatremic neuro-ICU patients Neurocrit Care 13 57 61 20568023 10.1007/s12028-010-9379-5
6. X Liu S Nakayama M Amiry-Moghaddam OP Ottersen A Bhardwaj 2010 Arginine-vasopressin V1 but not V2 receptor antagonism modulates infarct volume, brain water content, and aquaporin-4 expression following experimental stroke Neurocrit Care 12 124 131 19806476 10.1007/s12028-009-9277-x 1:CAS:528:DC%2BC3cXhslCisrw%3D
7. R Trabold S Krieg K Scholler N Plesnila 2008 Role of vasopressin V(1a) and V2 receptors for the development of secondary brain damage after traumatic brain injury in mice J Neurotrauma 25 1459 1465 19118456 10.1089/neu.2008.0597
8. K Taya S Gulsen K Okuno R Prieto CR Marmarou A Marmarou 2008 Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema Acta Neurochir 102 425 429 10.1007/978-3-211-85578-2- 83
9. E Kozniewska K Romaniuk 2008 Vasopressin in vascular regulation and water homeostasis in the brain J Physiol Pharmacol 59 Suppl 8 109 116 19258667
10. I Bemana S Nagao 1999 Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats Neurosurgery 44 148 154 9894975 10.1097/00006123-199901000-00091 1:STN:280:DyaK1M7htValtA%3D%3D (discussion 54-5) (Pubitemid 29016178)
11. M Kagawa S Nagao I Bemana 1996 Arginine vasopressin receptor antagonists for treatment of vasogenic brain edema: an experimental study J Neurotrauma 13 273 279 8797177 10.1089/neu.1996.13.273 1:STN:280:DyaK28zptVSrsQ%3D%3D (Pubitemid 26192775)
12. N Fernandez MA Martinez AL Garcia-Villalon L Monge G Dieguez 2001 Cerebral vasoconstriction produced by vasopressin in conscious goats: role of vasopressin V(1) and V(2) receptors and nitric oxide Br J Pharmacol 132 1837 1844 11309256 10.1038/sj.bjp.0704034 1:CAS:528:DC%2BD3MXjt1artrk%3D (Pubitemid 32397976)
13. Y Suzuki S Satoh M Kimura, et al. 1992 Effects of vasopressin and oxytocin on canine cerebral circulation in vivo J Neurosurg 77 424 431 1506890 10.3171/jns.1992.77.3.0424 1:CAS:528:DyaK38XmsVGkurg%3D
14. Y Suzuki S Satoh H Oyama M Takayasu M Shibuya K Sugita 1994 Vasopressin mediated vasodilation of cerebral arteries J Auton Nerv Syst 49 Suppl S129 S132 7836669 10.1016/0165-1838(94)90100-7 1:CAS:528:DyaK2cXmslamtLk%3D
15. S Tsugane Y Suzuki T Kano M Takayasu M Shibuya K Sugita 1994 Differing effects of vasopressin on regional cerebral blood flow of dogs following intracisternal vs. intra-arterial administration Life Sci 54 PL241 PL246 8152323 10.1016/0024-3205(94)00424-2 1:CAS:528:DyaK2cXitVyqtL8%3D (Pubitemid 24125003)
16. S Lluch MV Conde G Dieguez, et al. 1984 Evidence for the direct effect of vasopressin on human and goat cerebral arteries J Pharmacol Exp Ther 228 749 755 6707922 1:CAS:528:DyaL2cXhs1ylsbs%3D (Pubitemid 14156683)
17. S Adler JG Verbalis D Williams 1995 Effect of rapid correction of hyponatremia on the blood-brain barrier of rats Brain Res 679 135 143 7648255 10.1016/0006-8993(95)00245-L 1:CAS:528:DyaK2MXlsFCiu7o%3D